

CITATION REPORT

List of articles citing

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

DOI: 10.1080/15563650500514558

Clinical Toxicology, 2006, 44, 173-5.

Source: <https://exaly.com/paper-pdf/39758287/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
202	Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. 2006 , 45 Suppl 4, iv39-42		123
201	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. 2007 , 46, 808-10		90
200	The second hit: comorbidities in systemic lupus erythematosus. 2007 , 2, 497-506		2
199	A 73-year-old woman with rheumatoid arthritis and shortness of breath. 2008 , 59, 892-9		8
198	Rapid progression of atrioventricular nodal blockade in a patient with systemic lupus erythematosus. 2008 , 26, 967.e5-7		4
197	Antiprotozoal drugs. 2009 , 469-476		
196	Review article: systemic lupus erythematosus: a review for anesthesiologists. 2010 , 111, 665-76		35
195	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
194	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. 2010 , 69, 20-8		645
193	Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. 2011 , 364, 1450-60		34
192	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. 2012 , 42, 968-78		73
191	Severe primary hypothyroidism presenting with torsades de pointes. 2012 , 2012,		8
190	Chloroquine cardiomyopathy - a review of the literature. 2013 , 35, 434-42		120
189	Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. 2013 , 2, 77-83		92
188	Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease. 2013 , 22, 1070-6		9
187	Long QT Syndrome: An Emerging Role for Inflammation and Immunity. 2015 , 2, 26		79
186	Novel Therapies for Myocardial Irritability following Extreme Hydroxychloroquine Toxicity. 2015 , 2015, 692948		14

185	Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. 2015 , 70, 1608-21	258
184	Cardiorheumatology: cardiac involvement in systemic rheumatic disease. 2015 , 12, 168-76	111
183	Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. 2015 , 50, 410-9	30
182	Chloroquine and hydroxychloroquine. 2016 , 253-267	1
181	Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. 2016 , 2016, 4626279	54
180	Hydroxychloroquine, a potentially lethal drug. 2017 , 41, 257-259	
179	Hydroxychloroquine, a potentially lethal drug. 2017 , 41, 257-259	7
178	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. 2017 , 617-643	0
177	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. 2018 , 41, 919-931	195
176	Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. 2018 , 27, 1616-1623	12
175	Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology. 2019 , 9,	5
174	The effect of the severity COVID-19 infection on electrocardiography. 2021 , 46, 317-322	17
173	Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. 2020 , 29, 1689-1695	1
172	Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. 2020 , 20, 250-256	10
171	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. 2020 , 40, 978-983	4
170	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. 2020 , 108, 1135-1149	17
169	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. 2020 , 59, 337-345	17
168	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. 2020 , 28, 1760-1776	14

167	The "sex gap" in COVID-19 trials: a scoping review. 2020 , 29, 100652	21
166	Correspondence on ' : hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef. 2020 ,	4
165	Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19. 2020 , 130, 110582	18
164	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. 2020 , 62, 59-64	13
163	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. 2020 , 25, 497-502	2
162	Searching for COVID-19 treatments: First, do no harm. 2020 , 77, 1899-1905	2
161	Single Virus Targeting Multiple Organs: What We Know and Where We Are Heading?. 2020 , 7, 370	20
160	Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. 2020 , 43, 765-772	36
159	High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. 2020 , 34, 3400-3410	4
158	QTc Interval Prolongation and Life-Threatening Arrhythmias During Hospitalization in Patients With Coronavirus Disease 2019 (COVID-19): Results From a Multicenter Prospective Registry. 2021 , 73, e4031-e4038	13
157	rRT-PCR Results of a Covid-19 Diagnosed Geriatric Patient. 2020 , 2, 1-4	1
156	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. 2020 , 17, e1003252	55
155	A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. 2020 , 9,	21
154	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. 2020 , 9,	10
153	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. 2020 , 106192	6
152	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. 2020 , 37, 100747	11
151	Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. 2020 , 13, e008662	200
150	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. 2020 , 35, 101735	71

149	Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. 2020 , 17, 1417-1422	31
148	QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. 2020 , 17, 1425-1433	176
147	Advances in the relationship between coronavirus infection and cardiovascular diseases. 2020 , 127, 110230	38
146	May Polyphenols Have a Role Against Coronavirus Infection? An Overview of Evidence. 2020 , 7, 240	40
145	Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. 2020 , 12, 659-667	19
144	Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. 2020 , 17, 1487-1492	46
143	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. 2020 , 63, 12256-12274	111
142	Possible therapeutic agents for COVID-19: a comprehensive review. 2020 , 18, 1005-1020	13
141	A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation. 2020 , 9,	16
140	Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. 2020 , 141, e906-e907	108
139	Effects of hydroxychloroquine treatment on QT interval. 2020 , 17, 1930-1935	27
138	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. 2020 , 36, 101812	12
137	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. 2020 , 61, 597-606	17
136	QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection. 2020 , 108, 1090-1097	21
135	Tackling the cytokine storm in COVID-19, challenges and hopes. 2020 , 257, 118054	39
134	Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going. 2020 , 22, 680-684	11
133	Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. 2020 , 5, 986-987	22
132	Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment. 2020 , 75, 2623-2624	51

131	Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. 2020 , 6, 241-243	24
130	Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). 2020 , 95, 1213-1221	263
129	Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. 2020 , 13, 642-645	28
128	Antiviral treatment of COVID-19. 2020 , 50, 611-619	144
127	Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. 2020 , 113, 367-368	10
126	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020 ,	432
125	Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. 2020 , 40, 387-388	21
124	Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. 2020 , 17, e231-e232	13
123	Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin. 2020 , 75, 2992-2993	44
122	Hydroxychloroquine and "off-label" utilization in the treatment of oral conditions. 2020 , 129, 643-644	4
121	Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. 2020 , 108, 253-263	75
120	Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. 2021 , 17, 483-486	40
119	A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs. 2021 , 35, 205-214	13
118	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. 2021 , 19, 5-16	15
117	Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. 2021 , 7, 16-25	23
116	Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19. 2021 , 131, e9-e13	1
115	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. 2021 , 75, e13896	8
114	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. 2021 , 52, 261-269	6

113	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. 2021 , 5, 137-150	21
112	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. 2021 , 893, 173813	14
111	Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. 2021 , 155, 793-801	2
110	Hydroxychloroquine: Not a Heart Breaker!. 2021 , 73, 770-771	
109	Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus. 2021 , 73, 828-832	2
108	Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs. 2021 , 14, 20-28	22
107	Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. 2021 , 324, 242-248	12
106	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0
105	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. 2021 , 40, 1649-1657	1
104	Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. 2021 , 22, 190-196	1
103	Emerging therapeutics in the management of COVID-19. 2021 , 10, 1-29	2
102	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. 2021 , 180, 356-368	7
101	SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications. 2021 , 16, 18	1
100	COVID-19. 2021 , 203-210	
99	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review. 2021 , 203, 2043-2057	4
98	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1
97	QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. 2021 , 31, 1107-1112	3
96	Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients. 2020 , 11, 585021	2

95	Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility.	1
94	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. 2021 , 213, 113157	15
93	Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. 2021 , 14,	4
92	QT Interval in Patients With COVID-19. 2021 , 6, 357	0
91	Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. 2021 , 12, 631869	1
90	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. 2021 , 17, 371-387	31
89	SARS-CoV-2 Therapy: Old Drugs as New Interventions. 2021 , 2, 142-150	1
88	Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment. 2021 , 6, e132	1
87	Therapeutic approaches for SARS-CoV-2 infection. 2021 , 195, 29-43	5
86	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. 2021 , 23, 1124-1133	2
85	Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. 2021 , 16, e0251918	0
84	Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2. 2021 , 13,	5
83	Monitoring of QTc interval in patients with COVID-19. First experience with a portable ECG-recording device. 2021 , 28, 483-485	0
82	Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. 2021 , 17, 319-327	2
81	Predicting QT interval prolongation in patients diagnosed with the 2019 novel coronavirus infection. 2021 , 26, e12853	1
80	Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study. 2021 , 18, 102	4
79	Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience. 2021 , 7,	
78	Hydroxychloroquine Induced DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) Mimicking SARS-COV-2 Illness: A Case Report with Review. 2021 , 2, 521-526	

77	QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 Patients. 2021 , 16, 42	1
76	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). 2021 , 1	0
75	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. 2021 , 11, 676451	6
74	Validating and implementing cardiac telemetry for continuous QTc monitoring: A novel approach to increase healthcare personnel safety during the COVID-19 pandemic. 2021 , 67, 1-6	0
73	Hydroxychloroquine and Azithromycin Combination in The Management of COVID-19 Infection: Safety and Effectiveness Challenges. 2021 ,	
72	Mécanismes possiblement impliqués dans les effets antiviraux de la chloroquine et de l'hydroxychloroquine [Quelle référence pour le traitement de la COVID-19 ?]. 2021 , 33, 237-237	
71	Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. 2021 , 12, 722511	2
70	Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study. 2021 , 14, 1799-1809	0
69	Kombinierter Suizid: Methode nach Kusch und Kopfschuss Ein Fallbericht. 1	
68	New quinoline-triazole conjugates: Synthesis, and antiviral properties against SARS-CoV-2. 2021 , 114, 105117	11
67	Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. 2021 , 14, 5597-5606	2
66	Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA). 2021 , e13090	3
65	Rhythm Disorders in Endocrinology. 2021 , 7, 12	
64	Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases. 2021 , 5, 1-10	0
63	QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019. 2020 , 1, 167-172	8
62	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. 2020 , 38, 100770	10
61	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. 2020 , 42, 360-368	25
60	The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin.	41

59	Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19.	6
58	Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs.	3
57	Concentration-dependent mortality of chloroquine in overdose.	2
56	QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin.	19
55	Multi-omics study revealing putative drug targets of COVID-19 severity and other viral infection diseases.	7
54	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety: Systematic review of (hydroxy)chloroquine efficacy and safety.	1
53	Chloroquine, but not hydroxychloroquine, prolongs the QT interval in a primary care population.	1
52	Impact of sex and gender on COVID-19 outcomes in Europe. 2020 , 11, 29	496
51	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19. 2020 , 12, 604-611	6
50	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. 2020 , 58, 2047-2061	4
49	Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. 2020 , 61, 1056-1058	5
48	Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. 204-215	0
47	Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report. 2020 , 91, e2020123	2
46	CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab: foreign literature review. 2020 , 24, 96-104	2
45	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. 2020 , 11, 597985	13
44	QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19. 2020 , 114, 1061-1066	6
43	Prolongation of QT interval due to hydroxychloroquine overdose used in COVID-19 treatment. 2020 , 20, 149-151	3
42	Dentistry during and after COVID-19 Pandemic: Pediatric Considerations. 2020 , 13, 399-406	6

41	Concentration-dependent mortality of chloroquine in overdose. 2020 , 9,	17
40	A High Fidelity Transmural Anisotropic Ventricular Tissue Model Function to Investigate the Interaction Mechanisms of Drug: An In-Silico Model for Pharmacotherapy.	
39	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. 2021 , 73, 2151-2160	2
38	ANTIPROTOZOAL AND ANTIHELMINTHIC DRUGS. 2010 , 777-932	0
37	GLUCOCORTICOIDS AND DISEASE [MODIFYING ANTIRHEUMATIC DRUGS. 2010 , 371-667	
36	The Role of Inflammation and Autoimmunity in Long QT Syndrome. 2020 , 227-251	
35	I. Cloroquina / hidroxiclороquina y azitromicina. Revisi3n narrativa de seguridad. 2020 , 2, 71-82	
34	[QT Interval in Patients With COVID-19]. 2020 , 60, 11-14	1
33	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.	3
32	Progress in the risk assessment of hydroxychloroquine in frail elderly people. 2021 , 4, 53-57	
31	Glycemic efficacy and safety of hydroxychloroquine in type 2 diabetes mellitus: A systematic review and meta.analysis of relevance amid the COVID-19 pandemic. 2020 , 5, 184	0
30	Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician. 2020 , 33, 572-581	
29	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity.. 2021 , 6, 11502-11527	3
28	COVID-19 Management: What We Need to Know?. 2020 , 41, 441-445	
27	The effects and reliability of the hydroxychloroquine-azithromycin combination on the cardiac conduction system in patients with coronavirus disease 2019. 2020 , 4, 1082-1085	
26	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. 2021 , 17, 1187-1198	0
25	Repolarization in systemic sclerosis: a meta-analysis. 2021 , 1	
24	Hydroxychloroquine's Influence on Hypoxic and Hypokalemic ventricle: An Insilico Perspective. 2021 ,	

- 23 Comparison of hydroxychloroquine plus moxifloxacin versus hydroxychloroquine alone on corrected QT interval prolongation in COVID-19 patients. **2021**, 63, 564-571
- 22 Does the influence of hydroxychloroquine in a hypoxic ventricle differ from that of a non-hypoxic ventricle under congenital LQTS1 ?. **2021**,
- 21 Hydroxychloroquine- and Azithromycin-Induced Transient Left-Bundle Branch Block in a Patient with COVID-19. 92-97
- 20 Emerging risk factors for QT interval prolongation and torsades de pointes. **2022**, 113-156 0
- 19 Antimicrobial agents and torsades de pointes. **2022**, 231-266
- 18 Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. **2022**, 15, 1
- 17 Inhibition of SARS-CoV-2 infection in human iPSC-derived cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoarchitecture and beating.. **2021**, 9, e12595 1
- 16 Clinical characteristics and outcomes of COVID-19 in kidney transplant recipients. **2021**, 13, 339-355
- 15 Abordaje multifactorial del síndrome de QT largo adquirido en la COVID-19. **2020**, 5, 93-95
- 14 Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine treated systemic lupus erythematosus patients.. **2022**, 0
- 13 The effects of combined hydroxychloroquine and azithromycin therapy on QRS wave in COVID-19 patients. **2022**, 6, 483-487 0
- 12 Cardiovascular Involvement in Sjögren's Syndrome. **2022**, 13, 0
- 11 QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data.
- 10 The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. 0
- 9 Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2. **2022**, 451-488
- 8 Deacetylation mechanism and potential reversal strategy of long QT syndrome on hERG K+ channel under hypoxia. **2022**, 1868, 166487
- 7 Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study with 19-Year Follow-up. 0
- 6 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 6

- 5 Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: A historical cohort study. ○
- 4 Local Anesthetic Like Inhibition of the Cardiac Na⁺ Channel Nav1.5 by Chloroquine and Hydroxychloroquine. Volume 14, 353-365 ○
- 3 Sinus bradycardia and heart failure induced by short term use of low dose hydroxychloroquine: A case report. **2022**, ○
- 2 Chloroquine chaos and COVID-19: Smart delivery perspectives through pH sensitive polymers/micelles and ZnO nanoparticles. **2023**, 16, 104468 ○
- 1 Hydroxychloroquine Mitigates Dilated Cardiomyopathy Phenotype in Transgenic D94A Mice. **2022**, 23, 15589 ○